Search results
2 days ago · - Clopidogrel 300 mg loading dose should be given in patients undergoing PCI within 24 hours of receiving fibrinolytic therapy. Clopidogrel treatment should be continued at 75 mg once a day with ASA 75 mg – 100 mg daily. Combined therapy should be started as early as possible after symptoms start and continued up to 12 months (see section 5.1).
4 days ago · Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT.
4 days ago · Research has consistently shown that Clopidogrel besylate is effective in reducing the risk of further cardiovascular events in these high-risk patients. Ongoing studies are exploring its use in other conditions and refining its role in combination therapies. Clopidogrel besylate works by inhibiting the P2Y12 receptor on the surface ...
2 days ago · CABG within five days from clopidogrel is associated with modest increase in operative mortality and re-exploration for bleeding and substantial increase in blood product utilization. Risks decreased with increasing time from discontinuation, plateauing after 3 days from clopidogrel.
1 day ago · Ticagrelor, but not clopidogrel monotherapy, reduced MACE, NACE and mortality compared with standard DAPT, supporting its use after aspirin discontinuation. Protocol registration: This study is registered in PROSPERO (CRD42023494797).
3 days ago · There is general agreement that in most cases, treatment regimens with older anticoagulants (e.g., warfarin) and antiplatelet agents (e.g., clopidogrel, ticlopidine, prasugrel, ticagrelor, and/or aspirin) should not be altered before dental procedures.
2 days ago · Management of ischemic stroke has largely evolved over the past decades. A better understanding of stroke pathophysiology has allowed to identify patients who can benefit most from antiplatelet therapies, with varying degrees of benefit depending on whether these agents are being used for primary, s …
